Prior approval / evidence record
ASEAN member-state registration
- Authority
ASEAN member-state registration
- Benefit
There is no ASEAN mutual recognition agreement for device registration — the AMDD harmonises the dossier, not the decision
Maintained reference · planning ranges remain estimates · reviewed 2026-08-30
Prior approval / evidence record
Singapore HSA product registration — assessment report reliance
reliance.reliance-edge-hsa-to-thailand-reliance-approval-singapore-hsa-thailand
Fact-level verified↗- Source Approval
Singapore HSA product registration
- Edge Type
Assessment Report Reliance
- Market Access Strength
facilitated
- Regulatory Layer
Product Marketing
- Local Application Required
Yes
- Target Decision Retained
Yes
Conditions
- medical devices and IVDs subject to route-specific scope
- Singapore registrant consents to Thai FDA access to HSA evaluation report
Page also states verbatim: อย สามารถเข้าถึง evaluation report ที่ออกโดย HSA สิงคโปร์ได้ (Thai FDA can access the HSA evaluation report).
Prior approval / evidence record
EU CE under MDR/IVDR — abridged review
reliance.reliance-edge-big5-to-thailand-abridged-approval-eu-ce-mdr-ivdr-thailand
Fact-level verified↗- Source Approval
EU CE under MDR/IVDR
- Market Access Strength
facilitated
- Regulatory Layer
Product Marketing
- Local Application Required
Yes
- Target Decision Retained
Yes
- Marketing History Months
12
Conditions
- medical devices and IVDs subject to route-specific scope
- at least one year registration or approval history in a Big 5 reference jurisdiction
Page states the history condition verbatim: อย่างน้อย 1 ปีขึ้นไป.
Prior approval / evidence record
ASEAN Medical Device Directive (AMDD) harmonisation
- Name
ASEAN Medical Device Directive (AMDD) harmonisation
- Description
The AMDD gives the ten member states one device definition, one set of classification rules, one set of essential principles and one dossier structure, the Common Submission Dossier Template. It is not a reliance route. The ACCSQ Medical Device Product Working Group states in terms that the Directive is "not intended to confer mutual recognition" and that each member state retains the sovereign right to make its own registration decisions, so a registration in one ASEAN market authorises nothing in another and shortens no national review period.
- Timeline Reduction
None — the saving is in dossier preparation, since one CSDT core can be reused across member states with national addenda
- Eligibility
- Any device filed in an ASEAN member state that has transposed the AMDD into national law
Maintained reference · planning ranges remain estimates · reviewed 2026-08-30
Prior approval / evidence record
FDA 510(k)
- Benefit
Supports the Certificate of Free Sale and the CSDT technical evidence, but the Thai FDA publishes no shorter period for it
- Timeline Savings
None published
Maintained reference · planning ranges remain estimates · reviewed 2026-08-30
Prior approval / evidence record
EU CE Mark
- Benefit
Supports the Certificate of Free Sale and the CSDT technical evidence, but the Thai FDA publishes no shorter period for it
- Timeline Savings
None published
Maintained reference · planning ranges remain estimates · reviewed 2026-08-30
Prior approval / evidence record
Australia TGA/ARTG market authorization evidence — abridged review
reliance.reliance-edge-big5-to-thailand-abridged-approval-au-tga-thailand
Fact-level verified↗- Source Approval
Australia TGA/ARTG market authorization evidence
- Market Access Strength
facilitated
- Regulatory Layer
Product Marketing
- Local Application Required
Yes
- Target Decision Retained
Yes
- Marketing History Months
12
Conditions
- medical devices and IVDs subject to route-specific scope
- at least one year registration or approval history in a Big 5 reference jurisdiction
Page states the history condition verbatim: อย่างน้อย 1 ปีขึ้นไป.
Prior approval / evidence record
ASEAN Common Submission Dossier Template — harmonized dossier only
reliance.reliance-edge-asean-csdt-harmonization-standard-asean-csdt-thailand
Fact-level verified↗- Source Approval
ASEAN Common Submission Dossier Template
- Edge Type
Harmonized Dossier Only
- Market Access Strength
Evidence Only
- Regulatory Layer
Dossier Format
- Local Application Required
Yes
- Target Decision Retained
Yes
Conditions
- medical devices and IVDs subject to route-specific scope
- each national authority retains its own registration process
Thailand is party to the ASEAN agreement on medical-device provisions and aligns controls to it; Thai FDA registration-pathways page confirms submissions use รูปแบบ Common Submission Dossier Template (CSDT) — national registration and decision still required.
ThailandUS FDA · EU conformity assessment · Australia TGA · Health Canada · Japan MHLW / PMDA · WHO Prior approval / evidence record
Class 3
- Verification Status
official-verified
- Official Source
- Title
Thailand Ministerial Regulation B.E. 2563 — statutory review clocks (ข้อ ๕-๖)
- Url
https://medical.fda.moph.go.th/media.php?id=478924090456023040&name=กฏกระทรวงการแจ้งรายการละเอียดและการการออกใบรับแจ้งรายการละเอียดผลิตหรือนำเข้าเครื่องมือแพทย์ พ.ศ. 2563.pdf
- Prior Approval Benefits
- FDA
- EU CE Mark
- Japan
- TGA
- Health Canada
- WHO (for IVD)
- Notes
- Statutory cap: class-3 registration decided within 250 days (Ministerial Regulation B.E. 2563 ข้อ ๖)
- Fee payment due within 60 days of the invoice; submission receipt issued within 7 days of a complete file
- Clinical data may be required
- Clinical Trial Required
No
- Local Testing Required
Yes
Maintained reference · planning ranges remain estimates · reviewed 2026-08-30
ThailandUS FDA · EU conformity assessment · Australia TGA · Health Canada · Japan MHLW / PMDA · WHO Prior approval / evidence record
Class 2
- Verification Status
official-verified
- Official Source
- Title
Thailand Ministerial Regulation B.E. 2563 — statutory review clocks (ข้อ ๕-๖)
- Url
https://medical.fda.moph.go.th/media.php?id=478924090456023040&name=กฏกระทรวงการแจ้งรายการละเอียดและการการออกใบรับแจ้งรายการละเอียดผลิตหรือนำเข้าเครื่องมือแพทย์ พ.ศ. 2563.pdf
- Prior Approval Benefits
- FDA
- EU CE Mark
- Japan
- TGA
- Health Canada
- WHO (for IVD)
- Notes
- Statutory cap: class-2 registration decided within 250 days (Ministerial Regulation B.E. 2563 ข้อ ๖)
- Fee payment due within 60 days of the invoice; submission receipt issued within 7 days of a complete file
- ASEAN harmonization applies
- Clinical Trial Required
No
- Local Testing Required
Yes
Maintained reference · planning ranges remain estimates · reviewed 2026-08-30
Prior approval / evidence record
Health Canada medical-device licence — abridged review
reliance.reliance-edge-big5-to-thailand-abridged-approval-health-canada-thailand
Fact-level verified↗- Source Approval
Health Canada medical-device licence
- Market Access Strength
facilitated
- Regulatory Layer
Product Marketing
- Local Application Required
Yes
- Target Decision Retained
Yes
- Marketing History Months
12
Conditions
- medical devices and IVDs subject to route-specific scope
- at least one year registration or approval history in a Big 5 reference jurisdiction
Page states the history condition verbatim: อย่างน้อย 1 ปีขึ้นไป.
Regulatory reference
- Statement
Thai FDA offers two submission channels: the full pathway and the abridged evaluation pathway, the latter reserved for devices with a registration history from the agencies Thai FDA recognises: Australia TGA, Health Canada, EU Notified Bodies, Japan MHLW, US FDA and WHO Prequalification for IVDs. China's NMPA is not a recognised reference agency, so NMPA-registered devices are evaluated under the full pathway. The Singapore HSA reliance programme and the Malaysia MDA reliance programme (both held) are the only bilateral reliance channels and do not involve China.
- Source Jurisdiction Id
china
- Source Approval
China NMPA medical device registration certificate (Class II/III) or Class I filing record
- Target Jurisdiction Id
thailand
- China Classes In Scope
Class 2-4 devices and IVDs (detailed notification and licence routes); NMPA approvals do not qualify for the abridged pathway
- Edge Type
No Reliance Route
- Market Access Strength
none
- Regulatory Layer
Product Marketing
- Local Application Required
Yes
- Target Decision Retained
Yes
Conditions
- Abridged pathway requires at least one year of registration/approval history with a recognised agency (Big 5) per the Medical Device Control Division registration page
- Full CSDT dossier still required; abridged omits duplicate technical evaluation only
- Recognised-agency list formalised by FDA announcement B.E. 2567 (2024) on foreign agencies whose inspection or certification is accepted
- Independent verification is incomplete. Treat this record as a research lead, not a confirmed benefit or exclusion; see the 2026-09-15 independent review.
Effective from 2024-06-04
Source passage: 2. การประเมินเอกสารแบบย่อ (Abridged pathway) สำหรับเครื่องมือแพทย์ที่มีประวัติการขึ้นทะเบียนจากหน่วยงานที่ อย. รับรอง ดังนี้ Therapeutic Goods Administration: TGA; Health Canada: HC; European Union Notified Bodies: EU NB; Japan Ministry of Health Labour and Welfare: MHLW; US Food and Drug Administration: US FDA; WHO Prequalification of in Vitro Diagnostics (IVD)
Prior approval / evidence record
Japan MHLW/PMDA Ninsho or Shonin — abridged review
reliance.reliance-edge-big5-to-thailand-abridged-approval-japan-mhlw-pmda-thailand
Fact-level verified↗- Source Approval
Japan MHLW/PMDA Ninsho or Shonin
- Market Access Strength
facilitated
- Regulatory Layer
Product Marketing
- Local Application Required
Yes
- Target Decision Retained
Yes
- Marketing History Months
12
Conditions
- medical devices and IVDs subject to route-specific scope
- at least one year registration or approval history in a Big 5 reference jurisdiction
Page states the history condition verbatim: อย่างน้อย 1 ปีขึ้นไป.
Prior approval / evidence record
US FDA 510(k), De Novo, or PMA — abridged review
reliance.reliance-edge-big5-to-thailand-abridged-approval-us-fda-marketing-authorization-thailand
Fact-level verified↗- Source Approval
US FDA 510(k), De Novo, or PMA
- Market Access Strength
facilitated
- Regulatory Layer
Product Marketing
- Local Application Required
Yes
- Target Decision Retained
Yes
- Marketing History Months
12
Conditions
- medical devices and IVDs subject to route-specific scope
- at least one year registration or approval history in a Big 5 reference jurisdiction
Page states the history condition verbatim: อย่างน้อย 1 ปีขึ้นไป.
ThailandUS FDA · EU conformity assessment · Australia TGA · Health Canada · Japan MHLW / PMDA · WHO Prior approval / evidence record
Class 4
- Verification Status
official-verified
- Official Source
- Title
Thailand Ministerial Regulation B.E. 2563 — statutory review clocks (ข้อ ๕-๖)
- Url
https://medical.fda.moph.go.th/media.php?id=478924090456023040&name=กฏกระทรวงการแจ้งรายการละเอียดและการการออกใบรับแจ้งรายการละเอียดผลิตหรือนำเข้าเครื่องมือแพทย์ พ.ศ. 2563.pdf
- Prior Approval Benefits
- FDA
- EU CE Mark
- Japan
- TGA
- Health Canada
- WHO (for IVD)
- Notes
- Statutory cap: class-4 registration decided within 300 days (Ministerial Regulation B.E. 2563 ข้อ ๖)
- Fee payment due within 60 days of the invoice; submission receipt issued within 7 days of a complete file
- Clinical evidence required
- Clinical Trial Required
Yes
- Local Testing Required
Yes
Maintained reference · planning ranges remain estimates · reviewed 2026-08-30